762518

532067

3BBLACKBIO

img img img img
No Data Available

3b Blackbio Dx Ltd Share Price Update

3B BLACKBIO DX LTD. made its market debut on 2026-04-20 and is currently trading at ₹1300, down by ₹-18.00 from its previous close. Today's session has seen the stock move between ₹1281.00 and ₹1319.80.

3b Blackbio Dx Ltd performance

Today’s low Today’s high
₹ 1281.00 ₹ 1319.80
₹ 1299.60
52 week low 52 week high
₹ 1166.50 ₹ 1410.00
₹ 1299.60
Open Price ₹ 1308.70
Prev. Close ₹ 1318.00
Volume (Shares) 19427.00
Total traded value ₹ 252.47
Upper Circuit ₹ 1581.60
Lower Circuit ₹ 1054.40
info

Investment Returns

Over 1 Month 1.23% Over 3 Months 0.00% Over 6 Months 0.00% Over 1 Year 0.00%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

3b Blackbio Dx Ltd fundamentals


  • Market cap (Cr) 1,115.40
  • P/E Ratio (TTM) 22.10
  • Beta 0.97
  • Book Value / share 346.17
  • Return on equity 19.00%
  • EPS (TTM) 59.54
  • Dividend yield 0.30%
  • Net profit/quarter (Cr) 14.46
info icon alternate text
  • Market cap (Cr) 1,117.20
  • P/E Ratio (TTM) 22.10
  • Beta 1.10
  • Book Value / share 346.17
  • Return on equity 19.00%
  • EPS (TTM) 59.54
  • Dividend yield 0.30%
  • Net profit/quarter (Cr) 14.46
info icon alternate text

3b Blackbio Dx Ltd Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 24.38
Operating Expense 10.15
Net Profit 14.46
Net Profit Margin (%) 59.31
Earnings Per Share (EPS) 16.88
EBITDA 19.09
Effective Tax Rate (%) 23.32
Particulars SEP 2025 (Values in Cr)
Revenue 27.91
Operating Expense 12.29
Net Profit 14.94
Net Profit Margin (%) 53.52
Earnings Per Share (EPS) 17.44
EBITDA 19.75
Effective Tax Rate (%) 23.46
Particulars JUN 2025 (Values in Cr)
Revenue 20.36
Operating Expense 8.99
Net Profit 12.46
Net Profit Margin (%) 61.19
Earnings Per Share (EPS) 14.54
EBITDA 15.91
Effective Tax Rate (%) 20.53
Particulars MAR 2025 (Values in Cr)
Revenue 23.02
Operating Expense 13.78
Net Profit 9.24
Net Profit Margin (%) 40.13
Earnings Per Share (EPS) 10.79
EBITDA 14.37
Effective Tax Rate (%) 34.65
Particulars DEC 2024 (Values in Cr)
Revenue 23.43
Operating Expense 8.70
Net Profit 13.45
Net Profit Margin (%) 57.40
Earnings Per Share (EPS) 15.70
EBITDA 17.97
Effective Tax Rate (%) 24.13
Particulars MAR 2025 (Values in Cr)
Revenue 90.53
Operating Expense 41.63
Net Profit 47.56
Net Profit Margin (%) 52.53
Earnings Per Share (EPS) 55.51
EBITDA 64.89
Effective Tax Rate (%) 25.60
Particulars MAR 2024 (Values in Cr)
Revenue 70.72
Operating Expense 36.58
Net Profit 34.21
Net Profit Margin (%) 48.37
Earnings Per Share (EPS) 39.93
EBITDA 47.41
Effective Tax Rate (%) 26.33
Particulars MAR 2023 (Values in Cr)
Revenue 59.34
Operating Expense 30.75
Net Profit 26.42
Net Profit Margin (%) 44.52
Earnings Per Share (EPS) 35.27
EBITDA 36.84
Effective Tax Rate (%) 26.28
Particulars MAR 2022 (Values in Cr)
Revenue 15.52
Operating Expense 17.16
Net Profit 8.01
Net Profit Margin (%) 51.61
Earnings Per Share (EPS) 10.67
EBITDA 8.86
Effective Tax Rate (%) 5.43
Particulars MAR 2021 (Values in Cr)
Revenue 14.36
Operating Expense 16.00
Net Profit 1.72
Net Profit Margin (%) 11.97
Earnings Per Share (EPS) 2.29
EBITDA 2.51
Effective Tax Rate (%) 17.78
Particulars MAR 2025 (Values in Cr)
Book Value / Share 313.27
ROE % 19.41
ROCE % 26.03
Total Debt to Total Equity 0.00
EBITDA Margin 67.58
Particulars MAR 2024 (Values in Cr)
Book Value / Share 260.32
ROE % 15.42
ROCE % 21.20
Total Debt to Total Equity 0.01
EBITDA Margin 61.40
Particulars MAR 2023 (Values in Cr)
Book Value / Share 225.60
ROE % 14.98
ROCE % 20.24
Total Debt to Total Equity 0.01
EBITDA Margin 58.81
Particulars MAR 2022 (Values in Cr)
Book Value / Share 204.26
ROE % 22.59
ROCE % 29.92
Total Debt to Total Equity 0.02
EBITDA Margin 54.57
Particulars MAR 2021 (Values in Cr)
Book Value / Share 176.27
ROE % 138.73
ROCE % 179.45
Total Debt to Total Equity 0.03
EBITDA Margin 67.43
Particulars MAR 2025 (Values in Cr)
Book Value / Share 318.36
ROE % 19.00
ROCE % 25.53
Total Debt to Total Equity 0.00
EBITDA Margin 71.68
Particulars MAR 2024 (Values in Cr)
Book Value / Share 265.84
ROE % 16.14
ROCE % 21.82
Total Debt to Total Equity 0.01
EBITDA Margin 67.05
Particulars MAR 2023 (Values in Cr)
Book Value / Share 228.91
ROE % 24.01
ROCE % 32.09
Total Debt to Total Equity 0.02
EBITDA Margin 62.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 31.94
ROE % 34.39
ROCE % 33.57
Total Debt to Total Equity 0.10
EBITDA Margin 57.09
Particulars MAR 2021 (Values in Cr)
Book Value / Share 30.24
ROE % 7.92
ROCE % 9.48
Total Debt to Total Equity 0.13
EBITDA Margin 17.48
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 68.83
Total Assets 295.71
Total Liabilities 295.71
Total Equity 271.00
Share Outstanding 0
Price to Book Ratio 5.08
Return on Assets (%) 16.12
Return on Capital (%) 17.58
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 62.14
Total Assets 248.10
Total Liabilities 248.10
Total Equity 225.47
Share Outstanding 0
Price to Book Ratio 2.89
Return on Assets (%) 12.93
Return on Capital (%) 14.18
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 59.20
Total Assets 214.05
Total Liabilities 214.05
Total Equity 195.91
Share Outstanding 0
Price to Book Ratio 1.82
Return on Assets (%) 12.11
Return on Capital (%) 13.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 28.89
Total Assets 192.09
Total Liabilities 192.09
Total Equity 172.07
Share Outstanding 0
Price to Book Ratio 10.68
Return on Assets (%) 16.76
Return on Capital (%) 18.44
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 35.07
Total Assets 193.52
Total Liabilities 193.52
Total Equity 148.27
Share Outstanding 0
Price to Book Ratio 9.41
Return on Assets (%) 58.83
Return on Capital (%) 75.77
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 62.63
Total Assets 297.12
Total Liabilities 297.12
Total Equity 272.78
Share Outstanding 0
Price to Book Ratio 5.08
Return on Assets (%) 16.00
Return on Capital (%) 17.42
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 54.87
Total Assets 249.82
Total Liabilities 249.82
Total Equity 227.78
Share Outstanding 0
Price to Book Ratio 2.89
Return on Assets (%) 13.69
Return on Capital (%) 14.97
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 50.35
Total Assets 213.66
Total Liabilities 213.66
Total Equity 196.09
Share Outstanding 0
Price to Book Ratio 1.82
Return on Assets (%) 12.36
Return on Capital (%) 13.34
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.85
Total Assets 31.60
Total Liabilities 31.60
Total Equity 23.92
Share Outstanding 0
Price to Book Ratio 10.68
Return on Assets (%) 25.33
Return on Capital (%) 30.26
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.70
Total Assets 28.88
Total Liabilities 28.88
Total Equity 22.65
Share Outstanding 0
Price to Book Ratio 9.41
Return on Assets (%) 5.94
Return on Capital (%) 6.97
Particulars MAR 2025 (Values in Cr)
Net Income 63.99
Cash from Operations 58.14
Cash from Investing -33.84
Cash from Financing -3.21
Net change in Cash 6.29
Free Cash Flow 59.04
Particulars MAR 2024 (Values in Cr)
Net Income 44.33
Cash from Operations 37.79
Cash from Investing -20.31
Cash from Financing -3.62
Net change in Cash 3.00
Free Cash Flow 38.29
Particulars MAR 2023 (Values in Cr)
Net Income 35.30
Cash from Operations 29.22
Cash from Investing 14.73
Cash from Financing -5.00
Net change in Cash 30.01
Free Cash Flow 31.25
Particulars MAR 2022 (Values in Cr)
Net Income 43.22
Cash from Operations 47.88
Cash from Investing -28.44
Cash from Financing -15.07
Net change in Cash -6.18
Free Cash Flow 50.15
Particulars MAR 2021 (Values in Cr)
Net Income 152.03
Cash from Operations 135.40
Cash from Investing -70.25
Cash from Financing -1.56
Net change in Cash 25.69
Free Cash Flow 137.08
Particulars MAR 2025 (Values in Cr)
Net Income 63.92
Cash from Operations 59.31
Cash from Investing -33.63
Cash from Financing -3.07
Net change in Cash 7.75
Free Cash Flow 60.00
Particulars MAR 2024 (Values in Cr)
Net Income 46.44
Cash from Operations 39.30
Cash from Investing -20.31
Cash from Financing -3.61
Net change in Cash 4.52
Free Cash Flow 39.81
Particulars MAR 2023 (Values in Cr)
Net Income 35.84
Cash from Operations 30.14
Cash from Investing -7.80
Cash from Financing -2.89
Net change in Cash 10.46
Free Cash Flow 31.10
Particulars MAR 2022 (Values in Cr)
Net Income 8.46
Cash from Operations 8.14
Cash from Investing -1.52
Cash from Financing -6.30
Net change in Cash 0.14
Free Cash Flow 9.66
Particulars MAR 2021 (Values in Cr)
Net Income 2.08
Cash from Operations 3.18
Cash from Investing -0.17
Cash from Financing -1.59
Net change in Cash 1.02
Free Cash Flow 3.33
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
APOLLO HOSPITALS ENTERPRISE LT 7756.50 61.40 12.27 111526.57 6680.00 8099.00
FORTIS MALAR HOSPITALS LIMITED 56.37 23.29 3.07 105.65 40.75 81.00
SHREE PACETRONIX LTD. 139.95 21.11 3.09 52.48 66.10 283.15
TRANSGENE BIOTEK LTD. 3.05 0.00 2.50 23.11 1.83 5.26
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
APOLLO HOSPITALS ENTERPRISE LT 7756.50 76.79 11.97 111526.57 6680.00 8099.00
[-] 0.0 0.0 0.0 0.0 0.0 0.0
CHENNAI MEENAKSHI MULTISPECIAL 37.64 0.00 -10.93 28.12 30.02 57.48
KOVAI MEDICAL CENTER & HO 5714.20 26.51 5.25 6251.33 5010.00 6725.00

3b Blackbio Dx Ltd shareholding pattern

Holding
54.51%
40.94%
2.56%
1.98%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

3b Blackbio Dx Ltd Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1299.60 -1.39 redarrow
red-green-graph indicator
1 Bearish
15 Bullish
  • 5 Days 1286.10
  • 26 Days 1299.30
  • 10 Days 1300.20
  • 50 Days 1299.30
  • 12 Days 1299.30
  • 100 Days 1299.30
  • 20 Days 1299.30
  • 200 Days 1299.30
1265.73 PIVOT
First Support 1237.37 First Resistance 1311.37 Second Support 1191.73 Second Resistance 1339.73 Third Support 1163.37 Third Resistance 1385.37
RSI 51.68 ADX 15.92 MACD 0.00 Williams % R -37.78 Commodity Channel Index (CCI) 18.94
Date 2026-05-06 Week 7021.00 Same Day 8129.00 Month 5344.00
1 Year 0.97 3 Year 1.00
Over 1 Month
1.23% down
Over 1 Year
0.00% down
Over 3 Months
0.00% down
Over 3 Years
0.00% down
Over 6 Months
0.00% down
Over 5 Years
0.00% down

3b Blackbio Dx Ltd Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2025 4.0 Final 19 Sep 2025 Equity shares
17 Sep 2024 3.0 Final 18 Sep 2024 Equity shares
15 Sep 2023 2.5 Final 15 Sep 2023 Equity shares
14 Sep 2022 2.5 Final 16 Sep 2022 Equity shares
14 Sep 2021 8.0 Special 16 Sep 2021 Equity shares
14 Sep 2021 1.0 Final 16 Sep 2021 Equity shares
19 Mar 2020 0.7 Interim 20 Mar 2020 Equity shares
17 Sep 2019 0.5 Final 19 Sep 2019 Equity shares
17 Sep 2018 0.5 Final 19 Sep 2018 Equity shares
15 Sep 2017 0.3 Final 19 Sep 2017 Equity shares
19 Sep 2011 1.0 Final 21 Sep 2011 Equity shares
18 Sep 2007 1.0 Final 20 Sep 2007 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2025 4.0 Final 19 Sep 2025 Equity shares
17 Sep 2024 3.0 Final 18 Sep 2024 Equity shares
15 Sep 2023 2.5 Final 15 Sep 2023 Equity shares
14 Sep 2022 2.5 Final 16 Sep 2022 Equity shares
14 Sep 2021 8.0 Special 16 Sep 2021 Equity shares
14 Sep 2021 1.0 Final 16 Sep 2021 Equity shares
19 Mar 2020 0.7 Interim 20 Mar 2020 Equity shares
17 Sep 2019 0.5 Final 19 Sep 2019 Equity shares
17 Sep 2018 0.5 Final 19 Sep 2018 Equity shares
15 Sep 2017 0.3 Final 19 Sep 2017 Equity shares
19 Sep 2011 1.0 Final 21 Sep 2011 Equity shares
18 Sep 2007 1.0 Final 20 Sep 2007 Equity shares

Top Gainers

Top Losers

3b Blackbio Dx Ltd Share Price

3D Blackbio DX Limited, formerly known as Kilpest India Limited was incorporated on May 25, 1972 as one of India's leading agro-business companies. Thereafter, the holding Company, Kilpest India Limited got merged with 3B BlackBio Biotech India Limited and as per the Scheme of Amalgamation, the name of the Company was changed from Kilpest India Limited to 3B BlackBio DX Limited in August, 2023.

The Company is a leading Indian biotech firm focused on molecular diagnostics (PCR kits, enzymes, reagents for diseases like cancer/ infectious diseases) under the 'TRUPCR' brand, alongside developing Next-Gen Sequencing (NGS) assays (TRUNGS) & Rapid Tests (TRURAPID), while continuing its traditional agrochemicals business (pesticides, bio-products), serving both labs and government sectors, driven by R&D for innovative solutions.

The Company has representation in India in the field of agriculture business comprising crop protection, public health products and bio-products and is reputed reliable supplier to various Govt. organizations, such as Directorate General of Supplies & Transport, New Delhi, NAVY, Vishakapatnam/Mumbai, Food Corporation of India Raipur/ Bhopal/ Lucknow/ Mumbai/ Jaipur, NTPC, Bilaspur, Directorate of Health Service, M.P/Maharashtra/AP, Directorate of General Of Health Organization, Gujarat/U.P, Directorate General of Health services, MOH&FW (NVBDCP), Govt. of India, M/s Hindustan Latex Ltd, Noida, Director of Agriculture and Horticulture, M.P./Trivandrum, Central/Western Railway, Mumbai, Northern Railway, New Delhi etc. the company has nationwide distribution network of over 2000 dealers.

It possess well equipped R&D laboratory duly approved and recognized by DSIR, Ministry of Science and Technology, Government of India. Advanced instrumentation facility supported by equally competent team of scientists and technicians lay down a strong R&D foundation. Clean and hygienic environment ensure the consistency and reliability of results. Laboratory studies are planned, performed, monitored, recorded, applied in small scale field and then tabulated.

The products are manufactured to high International specifications with stringent quality control from raw material procurement to finished goods dispatch. The company's manufacturing process is complimented with the technical expertise and it has attained high standard suited to customer needs on 23-7-2002. Kilpest has received accreditation of International standard ISO 9001-2000 certified company. The companyhas diversified manufacturing in the field of micronutrients, bioproducts and plant growth regulators etc. The company is also exporting its products to Bangladesh and Afghanistan.

In 2011-12, the Company launched Novel Biotech Indo-Spanish Joint Venture Project in Govindpura, Bhopal, Madhya Pradesh. It ventured into Diagnostic Service.

In June, 2020, the Company launched , its single tube multiplex assay for TRUPCR SARS-CoV-2 RTqPCR Kit (Real-Time PCR based detection of SARS-CoV-2 virus) Version 3.2. With this, 3B BlackBio Biotech India Ltd. became first ever Indian molecular diagnostics company to receive US FDA-(EUA).

Company launched NGS based 'TRUNGSr Solid Tumor Panel' for detection of SNVs, Indels, CNVs and RNA fusions in 35 marker genes and hotspots in 6 pharmocogenomics genes associated with solid tumors such as lung, gastro-intestinal/colorectal, breast, liver and ovarian tumors in FY 2024.

The Rapid Kit manufacturing facility is made operational in 2025. The Company has added some novel products in Rapid Kit vertical for detection of Antimicrobial Resistance (AMR) genes. The Company has acquired Coris BioConcept SRL, Belgium in FY25.

Parent organization Indian Private
NSE symbol 3BBLACKBIO
Founded 1972
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of 3B Blackbio DX Ltd?

Answer Field

3B Blackbio DX Ltd share price is for NSE ₹ 1,300.00 & for BSE ₹ 1,310.60 as on May 07 2026 03:29 PM.

What is the Market Cap of 3B Blackbio DX Ltd Share?

Answer Field

The market cap of 3B Blackbio DX Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 07 2026 03:29 PM.

What is the 52 Week High and Low of 3B Blackbio DX Ltd?

Answer Field

The 52 Week High and Low of 3B Blackbio DX Ltd for NSE is ₹ 1,410.00 and ₹ 1,166.50 and for BSE is ₹ 2,019.90 and ₹ 1,110.00.

What is 1 year return for 3B Blackbio DX Ltd?

Answer Field

The 1 year returns on the stock has been 0.00%.

What is the P/E Ratio of 3B Blackbio DX Ltd Share?

Answer Field

As on May 07 2026 03:29 PM the price-to-earnings (PE) ratio for 3B Blackbio DX Ltd share is 22.10.

What is the PB ratio of 3B Blackbio DX Ltd Share?

Answer Field

As on May 07 2026 03:29 PM, the price-to-book (PB) ratio for 3B Blackbio DX Ltd share is 346.17.

How to Buy 3B Blackbio DX Ltd Share?

Answer Field

You can trade in 3B Blackbio DX Ltd shares with Bajaj Broking by opening a demat account.

How to Buy 3B Blackbio DX Ltd Share on Bajaj Broking App?

Answer Field

To buy 3B Blackbio DX Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “3B Blackbio DX Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|